Financial accounts reports

Issue  JCB, Volume 11, Number 1, 2004  Legal and Regulatory Updates 

Colin Aaronson

DOI:https://doi.org/10.5912/jcb106


Abstract:

Cambridge Antibody Technology plc (CAT) has established itself as a leader in the development of human monoclonal antibodies as new treatments for disease, based upon its own antibody technology. By mid-June 2004 it had one drug, HUMIRATM, a treatment for rheumatoid arthritis, approved in 41 countries including the USA and the UK, drug treatments for five conditions in Phase III and a number of other drugs at Phase I or II, or at the preclinical stage.

Keywords:en ,

Download PDF